期刊文献+

阿立哌唑与利培酮治疗精神分裂症的对照研究 被引量:11

A controlled study of aripiprazole and risperidone in treatment of schizophrenia
下载PDF
导出
摘要 目的比较阿立哌唑与利培酮对精神分裂症的疗效及安全性。方法将60例精神分裂症患者随机分为两组,阿立哌唑组30例,利培酮组30例,疗程8周。在治疗前及治疗2、4、6、8周末分别采用阳性与阴性症状量表(PANSS)评定疗效,以治疗中出现的症状量表(TESS)评定药物不良反应。结果两组治疗后PANSS评分均有显著下降,阿立哌唑组与利培酮组的显效率分别为76.7%和73.3%,疗效相当。阿立哌唑组锥体外系副作用、体重增加和月经周期改变较利培酮组少而轻,且对催乳素水平没有影响。结论阿立哌唑与利培酮对精神分裂症均有较好的疗效,但阿立哌唑的药物不良反应比利培酮少,且不影响催乳素水平,是一种有效、安全的抗精神病药物。 Objective To compare the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia.Methods 60 patients with schizophrenia were randomly divided into two groups: aripiprazole group(n=30) and risperidone group(n=30).The therapeutic effects were evaluated by PANSS,and side effects were assessed by TESS before and after 2,4,6 and 8 treatment weeks.Results The rates of marked improvement in aripiprazole group and risperidone group were 76.7% and 73.3%,respectively.Conclusion Both aripiprazole and risperidone have good effective in the treatment of schizophrenia.But aripiprazole has less adverse effects.It's an effective and safe antipsychotic drug.
出处 《西部医学》 2010年第6期1051-1052,共2页 Medical Journal of West China
关键词 阿立哌唑 利培酮 精神分裂症 疗效 安全性 Aripiprazole Risperidone Schizophrenia Efficacy Safety
  • 相关文献

参考文献3

二级参考文献32

  • 1黄文武,姜德国.抗精神病新药阿立哌唑[J].上海精神医学,2003,15(5):307-308. 被引量:153
  • 2施辉,徐乐平.服用过量感冒药致精神障碍3例[J].临床精神医学杂志,2005,15(3):172-172. 被引量:3
  • 3张作记.行为医学量表手册[J].中国行为医学科学,2001,:118-119.
  • 4久住一郎,小山司.抗精神病藥の開發動向と問題点[J].臨床精神醫學,2004,263-267.
  • 5Bowles TM, levin GM. Aripiprazole : A new atypical antipsychotic drug [ J ]. Ann pharmacother, 2003,37 : 687-694.
  • 6Murasaki M. AD-5423 versus haloperidol in the treatment of schizophrenic patients: results of the Japan multicentle, double-blind trial [ J ]. Eur Neuropsychopharmacol, 2002,12 : 5268.
  • 7Gunasekara NS, Spencer CM, Keating GM. Ziprasidone : a review of its use irt schizophrenia and schizoaffective disorder[ J ]. Drugs, 2002,62 :1217-1251.
  • 8堀澤智子,田頭利惠,藪内一輝,ほか.新規抗精神病藥SM-13496の藥理學的特性:腦内各種受容體にすと作用評價[J].日本神經精神藥理學雜志,1999,19;363.
  • 9Ogasa M,kimura T, Boylan M, et al. SM-13496 in patients with acute exacerbation of schizophrenia: a two-dosc double-blind phase Ⅱ comparison with placebo [ J ]. Schizophr Res, 2003,60 ( Suppl ) : 297.
  • 10Fleischhacker WW, Eerdekens M, Karcher k, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic[ J ]. J Chin Psychiatry, 2003,64 : 1250-1257.

共引文献303

同被引文献85

引证文献11

二级引证文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部